RESUMO
Introducción La enfermedad por coronavirus-19 (COVID-19) se ha relacionado con múltiples síntomas: respiratorios, trombóticos, neurológicos, digestivos o cutáneos. Estos últimos se han clasificado en 5 tipos: lesiones acroisquémicas, lesiones vesiculares, erupción urticarial, exantema maculopapular o lesiones livedoides. Sin embargo, se han descrito mucho menos las alteraciones orales asociadas a la COVID-19. Pacientes y métodos Presentamos un estudio transversal realizado durante abril del 2020 en el Hospital de Campaña de IFEMA examinando la mucosa oral de 666 pacientes con COVID-19. Resultados En total, 78 pacientes (11,7%) presentaron alteraciones en la mucosa oral. La más frecuente fue papilitis lingual transitoria anterior en forma de U (11,5%) asociada o no a edema lingual (6,6%); estomatitis aftosa (6,9%), mucositis (3,9%) glositis con depapilación en parches (3,9%), boca urente (5,3%), lengua saburral (1,6%) y enantema (0,5%). La mayoría refería disgeusia asociada. Conclusión La cavidad oral se puede alterar por la enfermedad COVID-19, el edema lingual con papilitis lingual transitoria en forma de U o la glositis con depapilación en parches son los signos encontrados con mayor frecuencia, al igual que la sensación de ardor en la cavidad oral o boca urente. Otras manifestaciones orales que se pueden asociar a la COVID-19 son mucositis con o sin aftas o el enantema. Todos pueden ser signos clave para un diagnóstico de esta enfermedad (AU)
Background Coronavirus disease 19 (COVID-19) has many manifestations, including respiratory, thrombotic, neurologic, digestive, and cutaneous ones. Cutaneous manifestations have been classified into 5 clinical patterns: acro-ischemic (pseudo-chilblain), vesicular, urticarial, maculopapular, and livedoid. Oral manifestations have also been reported, but much less frequently. Patients and methods We performed a cross-sectional study in which we examined the oral mucosa of 666 patients with COVID-19 at the IFEMA field hospital in Madrid in April 2020. Results Seventy-eight patients (11.7%) had changes involving the oral mucosa. The most common were transient anterior U-shaped lingual papillitis (11.5%) accompanied or not by tongue swelling (6.6%), aphthous stomatitis (6.9%), a burning sensation in the mouth (5.3%), mucositis (3.9%), glossitis with patchy depapillation (3.9%), white tongue (1.6%), and enanthema (0.5%). Most of the patients also reported taste disturbances. Conclusion COVID-19 also manifests in the oral cavity. The most common manifestations are transient U-shaped lingual papillitis, glossitis with patchy depapillation, and burning mouth syndrome. Mucositis with or without aphthous ulcers or enanthema may also be observed. Any these findings may be key clues to a diagnosis of COVID-19 (AU)
Assuntos
Humanos , Infecções por Coronavirus/complicações , Pandemias , Doenças da Boca/virologia , Mucosa Bucal/patologia , Hospitais de Emergência , Estudos TransversaisRESUMO
BACKGROUND: Coronavirus disease 19 (COVID-19) has many manifestations, including respiratory, thrombotic, neurologic, digestive, and cutaneous ones. Cutaneous manifestations have been classified into 5 clinical patterns: acro-ischemic (pseudo-chilblain), vesicular, urticarial, maculopapular, and livedoid. Oral manifestations have also been reported, but much less frequently. PATIENTS AND METHODS: We performed a cross-sectional study in which we examined the oral mucosa of 666 patients with COVID-19 at the IFEMA field hospital in Madrid in April 2020. RESULTS: Seventy-eight patients (11.7%) had changes involving the oral mucosa. The most common were transient anterior U-shaped lingual papillitis (11.5%) accompanied or not by tongue swelling (6.6%), aphthous stomatitis (6.9%), a burning sensation in the mouth (5.3%), mucositis (3.9%), glossitis with patchy depapillation (3.9%), white tongue (1.6%), and enanthema (0.5%). Most of the patients also reported taste disturbances. CONCLUSION: COVID-19 also manifests in the oral cavity. The most common manifestations are transient U-shaped lingual papillitis, glossitis with patchy depapillation, and burning mouth syndrome. Mucositis with or without aphthous ulcers or enanthema may also be observed. Any these findings may be key clues to a diagnosis of COVID-19.
Assuntos
COVID-19/complicações , Doenças da Boca/epidemiologia , SARS-CoV-2/isolamento & purificação , Dermatopatias/epidemiologia , COVID-19/diagnóstico , COVID-19/imunologia , COVID-19/virologia , Teste de Ácido Nucleico para COVID-19/estatística & dados numéricos , Feminino , Pé , Mãos , Humanos , Masculino , Pessoa de Meia-Idade , Unidades Móveis de Saúde/estatística & dados numéricos , Doenças da Boca/etiologia , Doenças da Boca/patologia , Mucosa Bucal/imunologia , Mucosa Bucal/patologia , Prevalência , RNA Viral/isolamento & purificação , SARS-CoV-2/imunologia , Índice de Gravidade de Doença , Pele/imunologia , Pele/patologia , Dermatopatias/etiologia , Dermatopatias/patologia , Espanha/epidemiologiaRESUMO
No disponible
Assuntos
Humanos , Dermatite de Contato/complicações , Azadirachta/efeitos adversos , Óleos de Plantas/efeitos adversos , Clobetasol/uso terapêutico , Dermatite Irritante/complicações , Testes CutâneosRESUMO
No disponible
Assuntos
Humanos , Masculino , Feminino , Gravidez , Adulto , Psoríase/complicações , Psoríase/terapia , Terapia Biológica/métodos , Terapia Biológica , Complicações na Gravidez/epidemiologia , Troca Materno-Fetal , Troca Materno-Fetal/imunologiaAssuntos
Adalimumab/uso terapêutico , Fármacos Dermatológicos/uso terapêutico , Etanercepte/uso terapêutico , Complicações na Gravidez/tratamento farmacológico , Psoríase/tratamento farmacológico , Ustekinumab/uso terapêutico , Anormalidades Induzidas por Medicamentos , Aborto Induzido , Adalimumab/efeitos adversos , Bases de Dados Factuais , Fármacos Dermatológicos/efeitos adversos , Etanercepte/efeitos adversos , Feminino , Ruptura Prematura de Membranas Fetais , Humanos , Recém-Nascido , Masculino , Gravidez , Sistema de Registros , Síndrome do Desconforto Respiratório do Recém-Nascido , Ustekinumab/efeitos adversosRESUMO
No disponible
Assuntos
Humanos , Masculino , Lactente , Hemangioma/complicações , Hemangioma , Hemangioma/tratamento farmacológico , Cardiopatias Congênitas/complicações , Cardiopatias Congênitas , Anormalidades do Olho/complicações , Propranolol/uso terapêutico , Angiografia Cintilográfica , Aorta Torácica/anormalidades , Aorta Torácica , Círculo Arterial do Cérebro/patologia , Círculo Arterial do CérebroRESUMO
No disponible
Assuntos
Humanos , Masculino , Adulto , Corticosteroides/efeitos adversos , Dermatite Alérgica de Contato/etiologia , Conservantes Farmacêuticos/efeitos adversos , Administração TópicaRESUMO
No disponible
Assuntos
Humanos , Psoríase/diagnóstico , Hidradenite/complicações , Psoríase/etiologia , Hidradenite/tratamento farmacológico , Anticorpos Monoclonais/uso terapêutico , Anti-Inflamatórios/uso terapêuticoAssuntos
Anticorpos Monoclonais/efeitos adversos , Toxidermias/etiologia , Hidradenite Supurativa/tratamento farmacológico , Psoríase/induzido quimicamente , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Anticorpos Monoclonais/uso terapêutico , Feminino , Humanos , Infliximab , Pessoa de Meia-IdadeRESUMO
El carcinoma epidermoide cutáneo (CEC) es la segunda neoplasia cutánea más frecuente y su incidencia está aumentando en las últimas décadas. La mayoría de los tumores se van a resolver con cirugía, pero alrededor de un 5% van a presentar metástasis locales y a distancia; esta proporción será mayor en algunos CEC que presenten determinados factores denominados de alto riesgo: tamaño tumoral (mayor de 2cm), profundidad de invasión (superior a 2mm), nivel de Clark (IV o superior), invasión perineural, invasión linfovascular, el grado de diferenciación (tumores pobremente diferenciados), tipo histológico (desmoplásico, adenoescamoso, enfermedad de Bowen invasiva o el CEC que aparece sobre un proceso inflamatorio crónico), inmunosupresión, infección por el virus del papiloma humano (VPH), localización en zonas de alto riesgo (pabellón auricular, mucosa labial), expresión de ciertos genes tumorales, o una inadecuada resección del tumor. La séptima y última clasificación TNM de la American Joint Committe on Cancer (AJCC) ha incluido algunos de estos factores de riesgo obteniendo de esta forma un mejor estadiaje. Realizamos una revisión de todos los factores de mal pronóstico del CEC y analizamos la nueva clasificación de la AJCC, así como las opciones terapéuticas del CEC de alto riesgo (AU)
Cutaneous squamous cell carcinoma (cSCC) is the second most common form of skin cancer and its incidence has increased in recent decades. Most cSCCs are successfully treated by surgery, but local and distant metastases develop in approximately 5% of cases; this proportion is higher in certain forms of cSCC with high-risk factors, namely: tumor size >2cm, depth >2mm, Clark level >IV, perineural invasion, lymphovascular invasion, poor differentiation, certain histologic subtypes (desmoplastic or adenosquamous carcinoma, invasive Bowen disease, or a cSCC arising in areas of chronic inflammation), immunosuppression, human papillomavirus infection, high-risk anatomic location (pinna of the ear, labial mucosa), expression of certain tumor genes, and inadequate tumor resection. The latest TNM (tumor, lymph node, metastasis) classification of cSCC published by the American Joint Committee on Cancer (AJCC) in the seventh edition of its Cancer Staging Manual now incorporates several of these risk factors to improve disease staging. We review all the factors currently considered to be markers of poor prognosis in cSCC and analyze the new AJCC classification and the different treatment options for high-risk cSCC (AU)
Assuntos
Humanos , Masculino , Feminino , Carcinoma de Células Escamosas , Carcinoma de Células Escamosas/cirurgia , Carcinoma de Células Escamosas/mortalidade , Carcinoma de Células Escamosas/prevenção & controle , Neoplasias Cutâneas , Fatores de Risco , Metástase Neoplásica , Recidiva Local de NeoplasiaAssuntos
Humanos , Masculino , Pessoa de Meia-Idade , Psoríase/diagnóstico , Psoríase/tratamento farmacológico , Anticorpos Monoclonais/uso terapêutico , Terapia PUVA/instrumentação , Terapia PUVA/métodos , Hiperceratose Epidermolítica/tratamento farmacológico , Ceratodermia Palmar e Plantar/complicações , Ceratodermia Palmar e Plantar/tratamento farmacológico , Terapia PUVARESUMO
Cutaneous squamous cell carcinoma (cSCC) is the second most common form of skin cancer and its incidence has increased in recent decades. Most cSCCs are successfully treated by surgery, but local and distant metastases develop in approximately 5% of cases; this proportion is higher in certain forms of cSCC with high-risk factors, namely: tumor size >2cm, depth >2mm, Clark level ≥IV, perineural invasion, lymphovascular invasion, poor differentiation, certain histologic subtypes (desmoplastic or adenosquamous carcinoma, invasive Bowen disease, or a cSCC arising in areas of chronic inflammation), immunosuppression, human papillomavirus infection, high-risk anatomic location (pinna of the ear, labial mucosa), expression of certain tumor genes, and inadequate tumor resection. The latest TNM (tumor, lymph node, metastasis) classification of cSCC published by the American Joint Committee on Cancer (AJCC) in the seventh edition of its Cancer Staging Manual now incorporates several of these risk factors to improve disease staging. We review all the factors currently considered to be markers of poor prognosis in cSCC and analyze the new AJCC classification and the different treatment options for high-risk cSCC.
